774 related articles for article (PubMed ID: 26317515)
21. Inhibition of crosstalk between Bcr-Abl and PKC signaling by PEITC, augments imatinib sensitivity in chronic myelogenous leukemia cells.
Roy M; Sarkar R; Mukherjee A; Mukherjee S
Chem Biol Interact; 2015 Dec; 242():195-201. PubMed ID: 26456889
[TBL] [Abstract][Full Text] [Related]
22. Anti-leukemic activity of valproic acid and imatinib mesylate on human Ph+ ALL and CML cells in vitro.
Kircher B; Schumacher P; Petzer A; Hoflehner E; Haun M; Wolf AM; Nachbaur D; Gastl G
Eur J Haematol; 2009 Jul; 83(1):48-56. PubMed ID: 19226363
[TBL] [Abstract][Full Text] [Related]
23. CD-200 induces apoptosis and inhibits Bcr-Abl signaling in imatinib-resistant chronic myeloid leukemia with T315I mutation.
Fang Z; Jung KH; Yan HH; Kim SJ; Son MK; Rumman M; Lee H; Kim KW; Yoo HD; Hong SS
Int J Oncol; 2015 Jul; 47(1):253-61. PubMed ID: 25963192
[TBL] [Abstract][Full Text] [Related]
24. 4-methylumbelliferone and imatinib combination enhances senescence induction in chronic myeloid leukemia cell lines.
Lompardía SL; Díaz M; Papademetrio DL; Pibuel M; Álvarez É; Hajos SE
Invest New Drugs; 2017 Feb; 35(1):1-10. PubMed ID: 27718039
[TBL] [Abstract][Full Text] [Related]
25. The autophagy induced by curcumin via MEK/ERK pathway plays an early anti-leukemia role in human Philadelphia chromosome-positive acute lymphoblastic leukemia SUP-B15 cells.
Guo Y; Shan QQ; Gong PY; Wang SC
J Cancer Res Ther; 2018; 14(Supplement):S125-S131. PubMed ID: 29578162
[TBL] [Abstract][Full Text] [Related]
26. Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells.
Yu C; Krystal G; Varticovksi L; McKinstry R; Rahmani M; Dent P; Grant S
Cancer Res; 2002 Jan; 62(1):188-99. PubMed ID: 11782377
[TBL] [Abstract][Full Text] [Related]
27. PI3K isoform inhibition associated with anti Bcr-Abl drugs shows in vitro increased anti-leukemic activity in Philadelphia chromosome-positive B-acute lymphoblastic leukemia cell lines.
Ultimo S; Simioni C; Martelli AM; Zauli G; Evangelisti C; Celeghini C; McCubrey JA; Marisi G; Ulivi P; Capitani S; Neri LM
Oncotarget; 2017 Apr; 8(14):23213-23227. PubMed ID: 28390196
[TBL] [Abstract][Full Text] [Related]
28. The study of resistant mechanisms and reversal in an imatinib resistant Ph+ acute lymphoblastic leukemia cell line.
Xing H; Yang X; Liu T; Lin J; Chen X; Gong Y
Leuk Res; 2012 Apr; 36(4):509-13. PubMed ID: 22285507
[TBL] [Abstract][Full Text] [Related]
29. [The Mechanism of Combination using mTORC1/2 Inhibitor and Imatinib to Suppress Cell Proliferation of Ph
Wu JH; Shi FF; Gong YP; Shi R
Sichuan Da Xue Xue Bao Yi Xue Ban; 2017 Mar; 48(2):216-220. PubMed ID: 28612529
[TBL] [Abstract][Full Text] [Related]
30. Idarubicin induces mTOR-dependent cytotoxic autophagy in leukemic cells.
Ristic B; Bosnjak M; Arsikin K; Mircic A; Suzin-Zivkovic V; Bogdanovic A; Perovic V; Martinovic T; Kravic-Stevovic T; Bumbasirevic V; Trajkovic V; Harhaji-Trajkovic L
Exp Cell Res; 2014 Aug; 326(1):90-102. PubMed ID: 24907655
[TBL] [Abstract][Full Text] [Related]
31. Distinct Dasatinib-Induced Mechanisms of Apoptotic Response and Exosome Release in Imatinib-Resistant Human Chronic Myeloid Leukemia Cells.
Liu J; Zhang Y; Liu A; Wang J; Li L; Chen X; Gao X; Xue Y; Zhang X; Liu Y
Int J Mol Sci; 2016 Apr; 17(4):531. PubMed ID: 27070592
[TBL] [Abstract][Full Text] [Related]
32. eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies.
Boussemart L; Malka-Mahieu H; Girault I; Allard D; Hemmingsson O; Tomasic G; Thomas M; Basmadjian C; Ribeiro N; Thuaud F; Mateus C; Routier E; Kamsu-Kom N; Agoussi S; Eggermont AM; Désaubry L; Robert C; Vagner S
Nature; 2014 Sep; 513(7516):105-9. PubMed ID: 25079330
[TBL] [Abstract][Full Text] [Related]
33. PI3K/mTOR dual-inhibition with VS-5584 enhances anti-leukemic efficacy of ponatinib in blasts and Ph-negative LSCs of chronic myeloid leukemia.
Kayabasi C; Yelken BO; Asik A; Okcanoglu TB; Sogutlu F; Gasimli R; Susluer SY; Saydam G; Avci CB; Gunduz C
Eur J Pharmacol; 2021 Nov; 910():174446. PubMed ID: 34461124
[TBL] [Abstract][Full Text] [Related]
34. Translation initiation complex eIF4F is a therapeutic target for dual mTOR kinase inhibitors in non-Hodgkin lymphoma.
Demosthenous C; Han JJ; Stenson MJ; Maurer MJ; Wellik LE; Link B; Hege K; Dogan A; Sotomayor E; Witzig T; Gupta M
Oncotarget; 2015 Apr; 6(11):9488-501. PubMed ID: 25839159
[TBL] [Abstract][Full Text] [Related]
35. The antiproliferation effect of berbamine on k562 resistant cells by inhibiting NF-kappaB pathway.
Wei YL; Liang Y; Xu L; Zhao XY
Anat Rec (Hoboken); 2009 Jul; 292(7):945-50. PubMed ID: 19548306
[TBL] [Abstract][Full Text] [Related]
36. Cryptotanshinone enhances the efficacy of Bcr-Abl tyrosine kinase inhibitors via inhibiting STAT3 and eIF4E signalling pathways in chronic myeloid leukaemia.
Cheng R; Huang Y; Fang Y; Wang Q; Yan M; Ge Y
Pharm Biol; 2021 Dec; 59(1):893-903. PubMed ID: 34214017
[TBL] [Abstract][Full Text] [Related]
37. Inducible SHP-2 activation confers resistance to imatinib in drug-tolerant chronic myeloid leukemia cells.
Li X; Pang J; Xue W; Wang Y; Tian T; Elgehama A; Wu X; Wu X; Sun Y; Qiu H; Shen Y; Xu Q
Toxicol Appl Pharmacol; 2018 Dec; 360():249-256. PubMed ID: 30290167
[TBL] [Abstract][Full Text] [Related]
38. Down-regulation of CD19 expression inhibits proliferation, adhesion, migration and invasion and promotes apoptosis and the efficacy of chemotherapeutic agents and imatinib in SUP-B15 cells.
Wu J; Liang B; Qian Y; Tang L; Xing C; Zhuang Q; Shen Z; Jiang S; Yu K; Feng J
Cell Biol Int; 2018 Sep; 42(9):1228-1239. PubMed ID: 29809305
[TBL] [Abstract][Full Text] [Related]
39. Local Anesthetic Drug Inhibits Growth and Survival in Chronic Myeloid Leukemia Through Suppressing PI3K/Akt/mTOR.
Zheng Q; Peng X; Yu H
Am J Med Sci; 2018 Mar; 355(3):266-273. PubMed ID: 29549929
[TBL] [Abstract][Full Text] [Related]
40. Rapamycin provides a therapeutic option through inhibition of mTOR signaling in chronic myelogenous leukemia.
Li J; Xue L; Hao H; Han Y; Yang J; Luo J
Oncol Rep; 2012 Feb; 27(2):461-6. PubMed ID: 21993902
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]